Topical glucocorticosteroids are frequently used for the treatment of sunburn despite the scarcity of randomized, double-blind controlled trials to support this indication. This randomized, intra-individually controlled trial compared the efficacy and safety of two topical glucocorticosteroids, 0.1% methylprednisolone aceponate milk (MPA) and 0.1% hydrocortisone 17-butyrate emulsion (HCB), for treatment of sunburn in 24 healthy volunteers of skin type III. After irradiation of the skin by simulated sunlight, treatments were blinded and randomly allocated to 36 cm 2 test areas on both sides of the spine. Volunteers were treated twice daily for 7 days and assessed daily with 1-day follow-up. The untreated area was not blinded. Primary efficacy measures were sum score and sunburn reaction based on erythema, oedema, burning and itching. Secondary efficacy measures were physician's global assessment, individual signs ⁄ symptoms, colorimetry, dermatological improvement, and time to healing. Intra-individual comparisons were made. Differences in sum score were apparent on days 3-4 and significant on days 4-5 for corticosteroids compared with nontreatment. Treated areas had significantly lower sunburn reaction than untreated areas (P ¼ 0.1% and P ¼ 0.5% for MPA and HCB, respectively). Differences between treatments were not significant. Secondary efficacy measures were in line with these findings. None of the three adverse events reported were considered to be related to treatment. We conclude that MPA and HCB are safe and effective in the treatment of sunburn.
Introduction
Sunburn is a common acute dermatitis in fair-skinned people with skin types I-III. 1 In a study of a randomly selected cross-sectional sample of 2025 adults in Great Britain, 37% had suffered at least one episode of sunburn in the preceding 12 months. 2 The acute sunburn reaction is a complex inflammatory process characterized clinically by erythema, and possible oedema, vesicles and ⁄ or weeping. Patients may report burning, itching and ⁄ or pain, and the severity of clinical manifestations and rate at which they evolve depend on the irradiation dose, wavelength, and degree of skin pigmentation.
Topical glucocorticosteroids, usually in lotion-type formulations, are frequently used to treat sunburn. 3, 4 To date, however, no randomized, double-blind controlled clinical trials have been reported to measure the benefit of topical glucocorticosteroids in the treatment of sunburn.
The present study was designed to investigate the efficacy and tolerability of topical 0.1% methylprednisolone aceponate milk (MPA) in the treatment of sunburn after irradiation of the skin by simulated sunlight in adults, in an intra-individual comparison to 0.1% hydrocortisone 17-butyrate emulsion (HCB), and an irradiated nontreated area. MPA is a nonhalogenated corticosteroid of potency class II according to Miller and Munro 5 with a double esterification that increases its lipophilic properties and thus its ability to penetrate the skin. 6 HCB, another class II corticosteroid, was chosen for comparison because its use in sunburn is widespread and it has an acceptable safety profile.
Materials and methods
Healthy volunteers of either sex had to be Caucasian of skin type II or III, 1 aged between 18 and 65 years, and without major abnormalities in their medical history. All volunteers signed informed consent prior to inclusion and the study was approved by an independent ethics committee. Prior to treatment, physical examination, laboratory tests, drug screening in all volunteers, plus a pregnancy test in female volunteers were performed.
Volunteers were to avoid direct contact with soap or synthetic detergents on the test areas throughout the study, excessive physical exercise and swimming, and exposure of the treated and nontreated areas and surrounding areas to sunlight. Drugs other than the investigational products were not permitted. Women had to agree to effective contraception during the study; oral contraceptives were allowed.
The minimal erythema dose (MED) of each subject was determined (day )1 to day 1) in the proximity of the test zones prior to irradiations and treatments. 7 Three test areas of 36 cm 2 each were defined on the back of each volunteer. The two test areas for the investigational products were located symmetrically on the left and right side of the spine. The distance between test sites was between 5 and 10 cm. Treatments were allocated randomly to these two areas using a computer-generated randomization list, and the application of treatments was double-blind on these two areas. The third test area for the nontreated area was below the test area on the left side of the spine. All areas were irradiated by simulated sunlight using a filtered high pressure Xenon lamp at a dose of three times the MED.
Volunteers were first treated topically with 70 lL 0.1% MPA milk and 70 lL HCB (approximately 2 lL ⁄ cm 2 for each treatment) nonocclusively 6 h after irradiation. The second application was given 20 h later, in the morning of study day 2. From days 2-7, the study medication was applied twice daily (once in the morning and once 8 h later) until symptoms disappeared or to a maximum of 7 days.
Baseline values for sunburn reaction were obtained at visit 1 6 h after the end of the irradiation. The next visits (days 2-7) took place each morning before the first application of the treatments. The last visit was performed on the morning of day 8.
Outcome measures are shown in Fig. 1 . Colorimetric measurements were used to evaluate the potential effect of the development of the UV-induced pigmentation on the clinical assessments. 8 Colorimetric measurements were performed each day for each volunteer on a control nonirradiated and nontreated test area of the back. The colorimetric difference from this control area was calculated for the three other test areas.
Mean and median values for outcome measures were calculated for each treated test area and the intra-individual differences between two test areas, respectively. To assess the importance of the observed intra-individual test area differences, these were compared using the paired t-test. Alpha was always set to 5%. As this was an exploratory study, no a-adjustment for multiple testing was made. The 95% confidence intervals are given for differences in sunburn reaction.
Results
Twenty-four volunteers (10 female, 14 male) aged 19-61 years (median age, 28 years) with skin type III were included. All volunteers completed the study according to protocol and were included in the analyses of efficacy and safety.
All irradiated skin areas showed severe erythema (score of 3 on the severity scale) after irradiation with simulated sunlight.
Treatment differences in the sum score were apparent on days 3-4 and statistically significant on days 4-5 for both corticosteroids compared with nontreatment (Fig. 2) .
Glucocorticosteroid-treated areas showed lower sunburn reaction compared with the untreated areas (MPA milk vs. nontreatment, P < 0.1%; HCB vs. nontreatment, P ¼ 0.5%; Table 1 ). The difference of sunburn reaction between treatments was not significant (P ¼ 16.2%).
In the physician's global assessment, all treated and nontreated areas showed at least moderate improvement at last visit, and higher proportions of treated areas had distinct improvement or healed than nontreated areas (Fig. 3) .
Erythema, itch and pain scores were comparable between treatments and better than nontreatment, and scores for oedema and burning sensation were comparable for treatments and nontreatment on most days (data not shown). Vesicles were observed only in one volunteer (day 7, all three test areas). Weeping was not observed.
Mean a* decreased from 19.3 at baseline to 12.4 (relative reduction, 35.8%) on day 8 for MPA, from 19.2 to 12.5 (34.9%) for HCB, and from 18.9 to 12.7 (32.8%) for nontreatment.
Dermatological improvement was greater on treated than on nontreated areas. For time to healing, treated areas that healed completely reached their endpoints on days 7 and 8, and nontreated areas were judged as healed on day 8, only. The peak sum score of the symptoms erythema, oedema, burning, and itching varied between 3 and 5 (mean 3.6) for MPA and between 3 and 4 (mean 3.5) for HCB. In most cases, the last day on which the individual peak of the sum score was obtained, was day 3 irrespective of treatment. Figure 2 At each evaluation time point, the sum score was calculated for each volunteer and area by adding the individual scores for erythema, oedema, burning and itching. Thus the sum score ranged from 0 (all symptoms absent) to 12 (all symptoms severe). Both preparations significantly reduced overall mean sum scores by the end of treatment (Advantan milk vs. nontreatment, P ¼ 0.1%; Alfason Crelo vs. nontreatment, and P ¼ 0.5%). The sum score dierence between treatments was not significant (P ¼ 16.2%). Figure 4 illustrates the evolution of the difference (delta values) calculated for each colorimetric component. In order to observe the variations on the same scale, the opposite values of delta L* and delta b* are drawn on the same figure as delta a*. The results show that, independently of test area, the greater differences compared to control were observed for the a* component, i.e. the redness of the skin (erythema), and that the greater amplitude of variation was observed for a* as well. During the day 3-5 period, there was an increase of delta L* (decrease of -delta L* on the figure), parallel to the decrease of delta a*, indicating a lightening of the skin mainly due to a decrease of erythema. During the same period, there was a slight increase of delta b*, indicating a yellowing of the skin probably due to the initiation of pigmentation. Thus the main change of skin colour concerned erythema. This can be observed especially during the day 4-5 period where both test areaas were significantly different from the untreated area.
Discussion
Various therapeutic and methodological approaches have been used to address the treatment of sunburn. One study showed favourable results against pain associated with experimental sunburn using a histamine antagonist. 9 Topical indomethacin, intradermal injections of triamcinolone hexacetonide and topical application of betamethasone valerate powder dissolved in ethanol have been compared for the prevention of erythema, with medication being applied topically or injected immediately after exposure of skin areas of three groups of young healthy volunteers with heterogenous grades of MED. 10 Topical indomethacin proved to be more effective than corticosteroids in suppressing the erythema in that study; however, the study did not attempt to treat, but to prevent UV erythema.
Previous studies of topical corticosteroids in the treatment of sunburn have shown mixed results. [11] [12] [13] However, these studies were beset by a number of methodological limitations, including nonstandardized irradiation.
The present study is the first to demonstrate the efficacy of topical glucocorticoids in sunburn using a randomized, controlled, intra-individual comparative design. MPA milk was compared intra-individually to HCB milk and to nontreatment in 24 healthy male and female adult volunteers during 1 week with twice daily application. Untreated areas could not be blinded, but served as an important control for visual and subjective assessment. A vehicle control was not used in this study as MPA milk had consistently been more efficacious than vehicle in three preliminary studies of UVB-induced erythema (1, 2 and 3 MED), albeit on smaller test areas Figure 3 The investigator made the global assessment of therapeutic effect by comparing the skin condition after the end of treatment with that before of therapy. This was performed on the morning after the last treatment day. The scale used was as follows: (20 mm diameter) and over a period of 3 days only. Based on preliminary findings, no influence of the vehicle on the acute sunburn except cooling and smoothing was expected.
Skin areas were irradiated with 3 MED, and treatment was applied 6 h after irradiation in all subjects. Both MPA and HCB were evaluated using a lotion-type formulation, which is considered to be the optimal vehicle for acute dermatitis such as sunburn.
14 The size and distance between test sites were adequate for visual and subjective assessment. The primary outcome measures were based on clinically relevant signs and symptoms. Sum scores based on symptom severity, as well as a categorical physician's global assessment have proven to be robust and readily applied by clinicians. [15] [16] [17] Ultraviolet-induced pigmentation is the result of two different phenomena: the immediate pigmentation, i.e. photo-oxidation of melanin precursors already present in the skin, and the induction of melanization. The former is due mainly to UVA and is no longer visible within several hours after 3 MED exposure. The latter is due mainly to UVB, becomes visible 3-4 days after irradiation and reaches a maximum after 8-10 days. Thus there was an adequate time window in this study during which visual assessment of erythema was not affected by pigmentation even in these subjects with skin type III. Measurement of skin redness in this study was performed objectively by colorimetry. A major advantage of the colorimetry technique is that it separates the red component, which was especially important in the present cohort with stronger pigmentation.
Based on the results of this study, we conclude that lotion-type preparations of 0.1% MPA and 0.1% HCB are safe and effective in the treatment of sunburn.
